S
Saby George
Researcher at Roswell Park Cancer Institute
Publications - 167
Citations - 14398
Saby George is an academic researcher from Roswell Park Cancer Institute. The author has contributed to research in topics: Nivolumab & Renal cell carcinoma. The author has an hindex of 31, co-authored 138 publications receiving 10182 citations. Previous affiliations of Saby George include Memorial Sloan Kettering Cancer Center & University of Texas Health Science Center at San Antonio.
Papers
More filters
Journal ArticleDOI
Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders
Alice Boilève,Maria I. Carlo,Philippe Barthélémy,Stéphane Oudard,Delphine Borchiellini,Martin H. Voss,Saby George,Christine Chevreau,Judith Landman-Parker,M-D. Tabone,DD Chism,Asim Amin,Mehmet Asim Bilen,Dominick Bossé,A Coulomb-L'hermine,Xiaoping Su,Toni K. Choueiri,Nizar M. Tannir,Gabrial G. Malouf +18 more
TL;DR: MITF family tRCC is an aggressive disease with similar responses to ICIs as clear-cell RCC, and mutations in bromodomain-containing genes might be associated with clinical benefit.
Journal ArticleDOI
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
James A. Eastham,Glenn Heller,Susan Halabi,J. Paul Monk,Himisha Beltran,Martin E. Gleave,Christopher P. Evans,Steven K. Clinton,Russell Z. Szmulewitz,Jonathan A. Coleman,David W. Hillman,Colleen Watt,Saby George,Martin G. Sanda,Olwen Hahn,Mary-Ellen Taplin,J. Kellogg Parsons,James L. Mohler,Eric J. Small,Michael J. Morris +19 more
TL;DR: The data do not support the routine use of neoadjuvant CHT and RP in patients with clinically localized, high-risk PC at this time, and any potential benefit must be weighed against toxicity.
Journal ArticleDOI
Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.
Joshua J. McFarlane,Mark D. Kochenderfer,Mark R. Olsen,Todd M. Bauer,Ana M. Molina,Ralph J. Hauke,James A. Reeves,Sunil Babu,Peter Van Veldhuizen,Bradley G. Somer,Vijay Gunuganti,Ian D. Schnadig,Saby George,Ray D. Page,Edward Arrowsmith,Rohit Jain,Joshua Zhang,M. Brent McHenry,Jennifer L. Johansen,Nicholas J. Vogelzang +19 more
TL;DR: Clinically meaningful efficacy was observed with responses in several histologies, supporting nivolumab as a treatment option for patients with advanced nccRCC, a patient population with high unmet need.
Journal ArticleDOI
Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
Nizar M. Tannir,David F. McDermott,Bernard Escudier,Hans J. Hammers,Osvaldo Rudy Aren,Elizabeth R. Plimack,Philippe Barthélémy,Victoria Neiman,Saby George,Camillo Porta,Thomas Powles,Frede Donskov,Marc-Oliver Grimm,Asim Amin,Scott S. Tykodi,Yoshihiko Tomita,Brian I. Rini,M. Brent McHenry,Shruti Shally Saggi,Robert J. Motzer +19 more
TL;DR: N+I demonstrated superior OS and ORR v S in intention-to-treat (ITT) and intermediate/poor-risk (IP) pts with aRCC in CheckMate 214 and response outcomes per indepen...